[HER-ErbB family of receptors and their ligands: mechanisms of activation, signals and deregulation in cancer].
The topic of this review is first to analyze in normal conditions the signal transduction pathways induced by members of the HER-ErbB receptor family and their ligands, and second, to decipher some deregulations occurring in various cancer types. As a result, new therapeutic opportunities will be mentioned.
L'Allemain
Gilles
G
ISBDC (Institut de signalisation, biologie du développement et cancer), CNRS UMR 6543, 28, avenue Valrose, 06108 Nice. lallemain@unice.fr
D066246:ErbB Receptors / Q000502:physiology*; D006801:Humans; D009369:Neoplasms / Q000503:physiopathology*; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000502:physiology*; D020893:Receptor, ErbB-3 / Q000502:physiology*; D066247:Receptor, ErbB-4; D015398:Signal Transduction; D016211:Transforming Growth Factor alpha / Q000378:metabolism; D018406:Virus Physiological Phenomena
D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases; D020893:Receptor, ErbB-3; D066247:Receptor, ErbB-4; D016211:Transforming Growth Factor alpha; C587689:ERBB4 protein, human